Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 4
2017 pubmed 47 citations

Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo.

d'Anglemont de Tassigny. Xavier X; Jayasena. Channa N CN; Murphy. Kevin G KG; Dhillo. Waljit S WS; Colledge. William H WH

Key Findings

  • KP-54 has a blood half‑life of about 32 minutes, while KP-10 clears in roughly 4 minutes.
  • A single peripheral injection of KP-54 sustains elevated LH levels for at least 2 hours; repeated KP-10 injections do not.
  • Only KP-54, not KP-10, activates brain GnRH neurons behind the blood‑brain barrier, indicating it can cross the BBB.

Practical Outcomes

  • For self‑experimenters aiming to modulate reproductive hormones, using KP-54 is likely more effective than KP-10 because it lasts longer and reaches the brain. A single dose of KP-54 may be sufficient, reducing the need for frequent injections. This insight can guide dosage timing and peptide choice for protocols targeting fertility, hormone balance, or related performance goals.

Summary

The study shows that the longer version of kisspeptin (KP-54) stays in the blood much longer than the short version (KP-10) and can actually get into the brain, leading to a prolonged boost in the hormone LH. Repeated doses of KP-10 can't mimic this effect, suggesting KP-54 is the better choice for lasting reproductive hormone activation when taken peripherally.

Abstract

Kisspeptins regulate the mammalian reproductive axis by stimulating release of gonadotrophin releasing hormone (GnRH). Different length kisspeptins (KP) are found of 54, 14, 13 or 10 amino-acids which share a common C-terminal 10-amino acid sequence. KP-54 and KP-10 have been widely used to stimulate the reproductive axis but data suggest that KP-54 and KP-10 are not equally effective at eliciting reproductive hormone secretion after peripheral delivery. To confirm this, we analysed the effect of systemic administration of KP-54 or KP-10 on luteinizing hormone (LH) secretion into the bloodstream of male mice. Plasma LH measurements 10 min or 2 hours after kisspeptin injection showed that KP-54 can sustain LH release far longer than KP-10, suggesting a differential mode of action of the two peptides. To investigate the mechanism for this, we evaluated the pharmacokinetics of the two peptides in vivo and their potential to cross the blood brain barrier (BBB). We found that KP-54 has a half-life of ~32 min in the bloodstream, while KP-10 has a half-life of ~4 min. To compensate for this difference in half-life, we repeated injections of KP-10 every 10 min over 1 hr but failed to reproduce the sustained rise in LH observed after a single KP-54 injection, suggesting that the failure of KP-10 to sustain LH release may not just be related to peptide clearance. We tested the ability of peripherally administered KP-54 and KP-10 to activate c-FOS in GnRH neurons behind the blood brain barrier (BBB) and found that only KP-54 could do this. These data are consistent with KP-54 being able to cross the BBB and suggest that KP10 may be less able to do so.

Study Information

Provider

pubmed

Year

2017

Date

2017-05-02T00:00:00.000Z

DOI

10.1371/journal.pone.0176821

Citations

47

References

48